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Abstract
A rapid, accurate and sensitive method was developed and validated for the determination of non-steroidal anti-inflammatory drugs, etodolac and diclofenac sodium in pharmaceutical preparations. The proposed method was based on the reaction of
these drugs with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-F) in buffer of pH 8.5 to yield a yellow, fluorescent product. The
method was validated for specificity, linearity, limit of detection, limit of quantification, precision, accuracy, recovery and robustness. Beer’s law is obeyed over the concentration range of 40 - 600 ng/mL for etodolac, 25 - 500 ng/mL for diclofenac sodium,
respectively. The detection limits were found to be 0.071 ng/mL for etodolac, 0.055 ng/mL for diclofenac sodium, respectively.
Statistical analysis of the results has been carried out revealing high accuracy and good precision. The proposed methods were
successfully applied for the determination of the drugs in their pharmaceutical preparations with good recoveries. The developed
methods were sensitive, accurate and simple. The results obtained by the proposed method were comparable with those obtained by
the official method.
Key words: spectrofluorimetry, derivatization, validation, anti-inflammatory drug

Introduction
Etodolac (ED), 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, and diclofenac sodium (DC),
2-(2,6-dichloranilino) phenylacetic acid (Figure 1) are
nonsteroidal anti-inflammatory drugs (NSAIDs)(1).
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Figure 1. Chemical structures of ED, DC and NBD-F.
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NSAIDs are used in humans and domestic animals
due to their anti-inflammatory, analgesic and anti-pyretic
effects(2). NSAIDs are non-selective inhibitors of prostaglandin biosynthesis in humans and indicated for the
acute or long-term treatment of the signs and symptoms
of rheumatoid arthritis and osteoarthritis (3).
Several methods have been described for the determination of ED in pharmaceutical preparations and plasma
and urine, including high performance liquid chromatography (HPLC)(4-7), gas chromatography (GC)(8-10), spectrofluorimetry(11) and spectrophotometry(12,13).
Regarding DC, many reports have been described
for its determination, in pharmaceutical preparations and
plasma and urine. The reports include UV-Visible spectroscopy(14-19), chemometry(20) spectrofluorometry(21-23), liquid
chromatography(24-32), titrimetry(33) and potentiometry(34-36).
In this study, a sensitive spectrofluorimetric method
with high reproducibility has been developed for the
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assay of ED and DC in pharmaceutical preparations by
means of the derivative formed with NBD-F, which is a
specific reagent in the analysis of primary and secondary
aliphatic amines. In literature research, ED and DC, for
the first time have been derivatized by a reagent and have
been determined by spectrofluorimetry.

MATERIALS AND METHODS
I. Materials
Standard compounds of ED and DC were supplied
from Sigma (St. Louis, MO, USA). Etol (400 mg) and
Voltaren (25 mg) were obtained from local pharmacy.
NBD-F was purchased from Fluka (Buchs, Switzerland).
Other chemicals were purchased from Merck (Darmstadt, Germany). All solvents were of analytical grade. An
aquaMAXTM water system (Young Instrument, Korea)
produced ultra pure analytical grade water.

V. Procedure for the Assay of the Tablets
(I) Etol (400 mg) Tablets
Twenty tablets were weighed, finely powdered,
and then a quantity of the powder equivalent to 100 mg
of ED was transferred into a 100-mL volumetric flask,
dissolved in 50 mL methanol, sonicated for 30 min,
completed to volume with the methanol, shaken well for
5 min, and filtered into a 100-mL calibrated flask and
then diluted to volume with methanol. Five milliliters of
the filtrates were then adjusted to 100-mL with methanol
in calibrated flask, and procedure followed as mentioned
under general procedure.
(II) Voltaren (25 mg) Tablets

Fluorescence measurements were performed with
a Shimadzu spectrofluorimeter Model RF-1501 (Kyoto,
Japan) equipped with a Xenon lamp.

Twenty tablets were weighed and powdered, and
then a quantity of the powder equivalent to 100 mg
of DC was transferred to a 100-mL volumetric flask
containing 50 mL of methanol. The flask was shaken
for 30 min, diluted to 100 mL with the same solvent,
and then filtered. Five milliliters volumes of the filtrates
were then adjusted to 100 mL with methanol in calibrated
flask, and procedure followed as mentioned under general
procedure.

III. Preparation of Stock and Standard Solutions

VI. Method Validation

The stock solutions (ED and DC) were dissolved
in methanol (1.0 mg/mL). The working standard solutions were prepared from stock solutions by dilution
(50 μg/mL).
A borate buffer (0.1 M) was prepared by dissolving
0.620 g of boric acid and 0.750 g of potassium chloride in
100 mL of water. The pH was adjusted to 8.5 with 0.1 M
sodium hydroxide solution and the volume was made up
to 200 mL with water.
The NBD-F solution was freshly prepared at
0.2 mg/mL in methanol. Solutions were stored at 4°C.

The methods were validated according to International Conference on Harmonization guidelines for validation of analytical procedures (37).

II. Apparatus

IV. General Procedure
An appropriate volume of 50 μg/mL working solution (8.0 - 120 μL of ED; 5.0 - 100 μL of DC) was transferred into 12-mL stoppered tubes. To each flask 100 μL
of borate buffer (pH 8.5) followed by 100 μL of NBD-F
solution were added and mixed well. The solutions were
heated in a thermo stated water bath at 70°C for 15 min
(30 min for DC), then left to cool and acidified with
100 µL of 0.1 N HCI. The derivatives were extracted
three times with 3.0 mL of chloroform. The combined
organic phases were adjusted to 10 mL with the chloroform. The fluorescence intensity was measured spectrofluorimetrically at λ ex 461 nm and λ em 521 nm against
blank prepared similarly. The DC-NBD derivative was
determined at λ ex 464 nm and λ em 521 nm.

(I) Specificity
The specificity of the method was investigated by
observing any interference encountered from these tablet
excipients, which did not interfere with the proposed
methods.
(II) Linearity
The linearity was evaluated by linear regression
analysis, which was calculated by the least square regression method. The calibration curves were constructed
by plotting concentration versus intensities, using linear
regression analysis. The calibration curves (F = aC + b)
were constructed by the plots of the fluorescence intensitiy (F) of the drugs versus the concentrations (C) of the
calibration standards.
(III) Limit of Detection (LOD) and Quantification (LOQ)
The limit of detection (LOD) and limit of quantification (LOQ) of drugs by the proposed methods were determined using calibration standards. LOD and LOQ were
calculated as 3.3 σ/S and 10 σ/S, respectively, where S is
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the slope of the calibration curve and σ is the standard
deviation of intercept of regression equation.
(IV) Precision and Accuracy
The precision and accuracy of the assay were determined by repeatability (intra-day) and intermediate
precision (inter-day). Repeatability was evaluated by
assaying samples, at same concentration and during the
same day. The intermediate precision was studied by
comparing the assays on different days. Five sample solutions were prepared and assayed.
(V) Recovery
The % recovery of the added pure drug was calculated as, % recovery = [(Ct - Cs)/Ca] × 100, where Ct is the
total drug concentration measured after standard addition; Cs, drug concentration in the formulation sample;
Ca , drug concentration added to the formulation.

The robustness of the method was evaluated during
the development by deliberate changes to the method
parameters. The factors chosen for this study were the pH,
temperature and volume of NBD-F.

Results and Discussion
I. Fluorescence Spectra
In the present study, NBD-F forms highly fluorescent derivatives with secondary amines, therefore, it was
chosen as a derivatizing reagent for ED and DC. Owing
to the presence of labile floride in the chemical structure of NBD-F, a daily fresh solution was prepared and
tested in the present study. It was found that ED and DC
react with NBD-F and forms yellow-colored fluorescent
derivatives.
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Figure 2. (A) Emission spectrum of the ED (400 ng/mL). (B) Exciation spectrum of the ED (400 ng/mL). (C) Exciation spectrum of the DC
(400 ng/mL). (D) Emission spectrum of the DC (400 ng/mL). (E) Emission spectrum of the blank.
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II. Optimization of the Reaction Conditions
The different experimental parameters affecting
the development of the reaction product and its stability
were carefully studied and optimized. Such factors were
changed individually while others were kept constant.
These factors include: pH, type of buffer, temperature,
time and concentration of reagents.
(I) Effect of pH
The influence of pH on the fluorescence intensity
of the reaction product was investigated using 0.1 M
borate buffer over the pH range of 8.0 - 10.0 (Figure 3).
Maximum fluorescence intensity was obtained at pH 8.5,
after which the fluorescence intensity of the reaction
product gradually decreased. Therefore, pH 8.5 was
chosen as the optimum pH for such study. Other buffers
having the same pH value such as phosphate buffer was
tried and compared with 0.1 M borate buffer. The borate
buffer was found to be superior to the phosphate buffer at
the same pH value since it gave the highest fluorescence
intensity value.

400

Fluorescence Intensity

This derivative exhibited maximum fluorescence
intensity (λ em) at 521 nm after its excitation at wavelength (λ ex) of 461 nm (464 nm for DC). The excitation
and emission spectra for the reaction product of the drug
with NBD-F are given in Figure 2A - E.

300
ED

200

DC
100
0

8

8.5

9

9.5

10

pH

Figure 3. Effect of pH on fluorescence intensity.

the use of chloroform may be attributed to lowering the
fluorescence of the blank reagent.
(V) Effect of the Hydrochloric Acid
The fluorescence of the hydrolysis product of
NBD-F, namely, 4-hydroxy-7-nitrobenzo-2-oxa-1,3-diazole (NBD-OH), is quenched by decreasing the pH of
the reaction medium to less than one. It is known that
the maximum association between NBD-F and aimed
compound is realized at the basic medium. But, NBD-F
is also hydrolyzed in alkaline solution. Thus, the system
stabilized by acidifying the reaction mixture to pH 2 (by
adding 100 µL 1N HCl) before measurement (38) .

(II) Effect of Temperature and Time

(VI) Stability of the Fluorophore

The effect of temperature on the color intensity was
studied in the range from 50 to 80°C for different periods
of time. The color intensity increased on increasing the
applied temperature up to 70°C. The effect of the reaction
time on the reaction course was studied by measuring the
corresponding fluorescence intensity at constant temperature for different periods of time. It was found that the
optimum reaction time is 15 min (30 min for DC).

The NBD derivative was stable in chloroform for at
stable at room temperature in the dark for 6 h, in daylight
for 4 h and 8 days at 4°C in the dark.

(III) Effect of Concentration of NBD-F
Studying the effect of different NBD-F reagent
concentrations on the produced fluorescence intensity
revealed that highest fluorescence intensity was over
the concentration of NBD-F reagent in the final solution
between 0.01 and 0.04% (w/v). Therefore, the concentration of 0.02% (w/v) was selected for further experiments.
(IV) Effect of Diluting Solvent
Different solvents (methanol, acetonitrile, dichloromethane, chloroform and ethyl acetate) were tried to
dilute the reaction mixture throughout the study. It was
observed that chloroform gave the highest fluorescence
intensity. The increase of fluorescence intensity due to

III. Method Validation
(I) Specificity
The specificity of the method was investigated by
observing any interference encountered from common
excipients of the pharmaceutical formulation such as
lactose, microcrystalline cellulose, povidone, magnesium
stearate, starch-maize, iron oxide yellow and titanium
dioxide. It was found that these compounds did not interfere with the results of the proposed methods.
(II) Linearity
By using the above procedure, a linear regression
equation was obtained. The regression plots showed that
there was a linear dependence of the fluorescence signal
on the concentration of the drugs over the range cited in
Table 1. The linear regression analysis of the data gave
the following equation:
F = 0.5318C + 163.74 (r = 0.9996) for ED
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F = 0.6461C + 177.72 (r = 0.9998) for DC
where F is the fluorescence signal, C is the concentration of
the drug in ng/mL and r is the correlation coefficient. As can
be seen from the data, the method is much more sensitive
than most of the reported methods (11-23,32,34-36).
(III) LOD and LOQ
LOD were 0.071 ng/mL for ED, 0.055 ng/mL for
DC. LOQ of ED and DC were 0.213 and 0.165 ng/mL,
respectively. These results are given in Table 1, which is
as good as that reported in other papers (11-23, 32,34-36).
(IV) Precision and Accuracy
Repeatability was determined by using different
Table 1. Performance data of the proposed procedure (n = 5)
Parameter

ED-NBD

DC-NBD

λex

461

464

λem

521

521

40 - 600

25 - 500

Correlation coefficient (r)

0.9996

0.9998

Slope

0.5318

0.6461

Intercept

163.74

177.72

1.15 × 10-2

1.08 × 10-2

LOD (ng/mL)

0.071

0.055

LOQ (ng/mL)

0.213

0.165

Linear range (ng/mL)

Standard deviation of the
intercept

drug concentrations prepared from independent stock
solution and analyzed (n = 5). Inter-day and intra-day
variations were taken to determine precision of the
proposed methods. Different levels of drug concentrations
in triplicates were prepared thrice in a day and studied
for intra-day variation. The same method was followed
for three different days to study inter-day variation. The
calculated relative standard deviation values were found
to be very small below 2% indicating good repeatability
and reliability of the proposed methods. The results and
their statistical analysis were summarized in Table 2.
(V) Recovery
The recovery study was performed by adding known
amounts of the compounds studied to a known concentration of the commercial pharmaceutical tablets (standard
addition method, Table 3). These values are better than
those obtained by other methods (16,25).
(VI) Robustness
The robustness of the method adopted is demonstrated by the constancy of the fluorescence intensity
with the deliberated minor change in the experimental
parameters such as the change in the volume of NBD-F
(0.02%) ± 5.0 μL and the change in the heating temperature (70 ± 1°C) and pH 8.5 ± 0.1. These minor changes
that may take place during the experimental operation
did not affect the fluorescence intensity of the reaction
product (Table 4).
(VII) Stoichiometry of the Reaction
The Job’s method (39) of continuous variation was
employed. Master equimolar (1.74 × 10 -4 M for ED and

Table 2. Intra-day and inter-day precision and accuracy of ED and DC-NBD derivatives (n = 5)
Intra-day
Added
(ng/mL)

Inter-day

Mean ± SD
Found (ng/mL)

RSD (%)

RME (%)

40

39.3 ± 0.6

1.5

-1.8

100

101.2 ± 0.5

0.5

600

599.2 ± 0.6

25

Added
(ng/mL)

Mean ± SD
Found (ng/mL)

RSD (%)

RME (%)

40

39.5 ± 0.5

1.2

-1.3

1.2

100

101.7 ± 0.4

0.4

1.7

0.1

- 0.1

600

601.3 ± 1.1

0.2

0.2

25.1 ± 0.1

0.4

0.4

25

24.8 ± 0.2

0.8

-0.7

250

251.2 ± 1.2

0.5

0.5

250

249.2 ± 0.8

0.3

-0.3

500

498.8 ± 1.0

0.2

-0.2

500

501.5 ± 0.9

0.2

-0.3

ED-NBD

DC-NBD
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Table 3. Recovery studies of ED and DC (n = 5)

300

Concentration of pure
drug added (ng/mL)

Recovery ±
RSD (%)

ED
50

550

101.3 ± 0.2

50

250

101.1 ± 0.3

50

150

99.1 ± 0.5

DC

250

Fluorescence Intensity

Concentration of drug
in formulations (ng/mL)

200

ED

150
100
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0

0
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2

NBD-F/Drugs mole ratio

DC
50

450

99.5 ± 0.2

50

250

99.2 ± 0.3

50

150

98.7 ± 0.7

Figure 4. Mole ratio of DC and ED to NBD-F.
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Table 4. Robustness of the proposed method
Conditions

O

Mean ± SD
Cl

ED-NBD
(100 ng/mL)

NBD-F

Etodolac

DC-NBD
(250 ng/mL)

H
N

NO2

ONa

95 μL

101.3 ± 0.6

250.2 ± 0.8

105 μL

101.6 ± 0.8

250.2 ± 1.2

8.4

101.2 ± 0.6

250.1 ± 0.6

8.6

101.2 ± 0.6

250.1 ± 0.7

69°C

101.2 ± 0.6

250.1 ± 0.6

71°C

101.2 ± 0.6

250.1 ± 0.6

pH
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F

Cl
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Figure 5. The reaction between drugs and NBD-F.

Table 5. Determination of ED and DC in its pharmaceutical formulations (tablets) by the proposed spectrofluormetric and the official
methods
% Mean ± SD
Proposed
method

Official
method (40,41)

t

F

Etol (400 mg)

101.2 ± 0.6

101.5 ± 1.0

0.9

2.7

Voltaren (25 mg)

99.4 ± 0.4

99.8 ± 0.6

1.9

2.2

Reaction temp.

*n = 6, p = 0.05, t = 2.23, F = 5.05

1.27 × 10 -4 M for DC) solutions of drugs and NBD-F
were prepared. Series of 10 mL portions of the master
solutions of drugs and NBD-F were made up comprising
different complementary proportions in 12-mL screwcapped test tubes containing 100 µL of buffer solution (pH 8.5). The solution was further manipulated
as described under the general procedures. It is clear
that only one amino group of ED and DC molecules are
involved in the reaction with NBD-F and hence the molar
ratio is 1:1 (Figures 4 and 5).
(IV) Application
The proposed method has been successfully applied
to the determination of the studied drugs in commercial

tablets. The results obtained are shown in Table 5.
According to the t- and F-tests, no significant difference
were found between the calculated and theoretical values
of both the proposed and the official methods (40,41) at
95% confidence level. This indicates good level of precision and accuracy.

ConclusionS
The proposed method is accurate, time saving,
simple, sensitive and reproducible. The proposed method
is sensitive enough to determine small amounts of these
drugs, therefore can be used for quality control and
routine determination of drugs in pharmaceutical tablets

100
Journal of Food and Drug Analysis, Vol. 19, No. 1, 2011

where precision, time and cost effectiveness of analytical
methods are important.
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